Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis

European Journal of Surgical Oncology

Volumn 33, Issue 1, 2007, Pages 61-66

  Tabone, M ^a   Vigano', L ^b   Ferrero, A ^b   Pellerito, R ^a   Carbonatto, P ^a   Capussotti, L ^b  

^a MAURIZIANO HOSPITAL   (Italy)

^b IRCC Candiolo   (Italy)

Author keywords

131 Iodine labeled lipiodol; Hepatocellular carcinoma; Liver resection; Liver surgery; Recurrence

Indexed keywords

IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTE COUNT; VASCULAR TUMOR;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; IODIZED OIL; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846394107     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.10.039     Document Type: Article

References (26)

1. Tung-Ping Poon R., Tat Fan S., Oi-Ling Ng I., Lo C., Liu C.-L., and Wong J. Different risk factors and prognosis for early and slow intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89 (2000) 500-507
2. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and slow phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 (2003) 200-207
3. Lau W.Y., Leung T.W., Ho S.K., et al. Adiuvant intra-arterial iodine-131 labelled lipiodol for resectable hepatocellular carcinoma. A prospective randomised trial. Lancet 353 (1999) 797-801
4. Boucher E., Corbinais S., Rolland Y., et al. Adiuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38 (2003) 1237-1241
5. Capussotti L., Muratore A., Amisano M., Polastri R., Bouzari H., and Massucco P. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival - a European single center experience. Eur J Surg Oncol 31 (2005) 986-993
6. Yamamoto J., Kosuge T., Takayama T., et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83 (1996) 1219-1222
7. Mion F., Grozel L., Boillot O., Paliard P., and Berger F. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology 111 (1996) 1587-1592
8. Caroli-Bottino A., Nascimento C.M., Basto S., et al. Hepatocellular carcinoma: incidental finding in cirrhotic explanted livers. Transplant Proc 37 (2005) 2791-2792
9. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
10. Llovet J.M., Bruix J., Fuster J., et al. Liver transplantation for small hepatocellular carcinoma: the TNM classification does not have prognostic power. Hepatology 27 (1998) 1572-1577
11. Stroffolini T., Sagnelli E., Mele A., Craxi A., and Almasio P. Italian hospitals collaborative group. The aetiology of chronic hepatitis in Italy; results from a multicentre national study. Dig liver Dis 36 (2004) 829-833
12. www.ministerosalute.it/trapianti/normativa/statistiche.jsp
13. Mazziotti A., Grazi G.L., and Cavallari A. Surgical treatment of hepatocellular carcinoma on cirrhosis: a western experience Hepatogastroenterology 45 Suppl. 3 (1998) 1281-1287
14. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
15. Uchiyama K., Ueno M., Hama T., et al. Recurrence of primary hepatocellular carcinoma after hepatectomy - differences related to underlying hepatitis virus species. Hepatogastroentrology 52 (2005) 591-595
16. Heathcote J.E. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 (2004) S294-S302
17. Tabone M., Vigano' L., Laudi C., Ferreo A., Pellerito R., and Capussotti L. Adjuvant iodine-131-labeled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: which is the best treatment schedule?. Hepatology 41 6 (2005) 1433
18. Partensky C., Sassolas G., Henry L., Paliard P., and Maddern G.J. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 135 (2000) 1298-1300
19. Salem R., Lewandowski R., Roberts C., et al. Use of Yttrium-90 glass microspheres (Therasphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 15 (2004) 335-345
20. Salem R., Thurston K.G., Carr B.I., Goin J.E., and Geschwind J.F. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13 (2002) S223-S229
21. Sundram F., Minh Chau T.C., Onkuudai P., Bernal P., and Padhy K.A. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 250-257
22. Lambert B., Bacher K., Defreyne L., et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46 (2005) 60-66
23. Kumar A., Srivastava D.N., and Bal C. Management of postsurgical recurrence of hepatocellular carcinoma with rhenium 188-HDD labeled iodized oil. J Vasc Interv Radiol 17 (2006) 157-161
24. Kubo S., Nishiguchi S., Hirohashi K., et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus related hepatocellular carcinoma. Ann Intern Med 134 (2001) 963-967
25. Shiratori Y., Shiina S., Teratani T., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003) 299-306
26. Mazzaferro V., Romito R., and Colombo M. Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report. J Hepatol 40 Suppl. 1 (2004) A94